307,800 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Nomura Holdings Inc.

Nomura Holdings Inc. acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 307,800 shares of the medical research company's stock, valued at approximately $56,820,000. Nomura Holdings Inc. owned about 0.60% of Charles River Laboratories International at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CRL. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new position in Charles River Laboratories International during the fourth quarter worth about $37,000. GeoWealth Management LLC increased its stake in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at approximately $48,000. Finally, Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the period. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $0.58 during midday trading on Monday, hitting $140.39. The company had a trading volume of 214,626 shares, compared to its average volume of 979,760. The company has a market capitalization of $6.90 billion, a PE ratio of 934.47, a P/E/G ratio of 4.54 and a beta of 1.50. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The stock's fifty day moving average price is $135.43 and its 200-day moving average price is $164.76.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.27 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CRL. Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a report on Thursday, May 8th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Robert W. Baird increased their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average target price of $172.31.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Foster bought 6,075 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 5,040 shares of company stock worth $807,407. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).